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Abstract
The molecular pathogenesis of pediatric pilocytic astrocytoma (PA) is not well defined. Previous cytogenetic and
molecular studies have not identified nonrandom genetic aberrations. To correlate differential gene expression and
genomic copy number aberrations (CNAs) in PA, we have used Affymetrix GeneChip HG_U133A to generate gene
expression profiles of 19 pediatric patients and the SpectralChip 2600 to investigate CNAs in 11 of these tumors.
Hierarchical clustering according to expression profile similarity grouped tumors and controls separately. We iden-
tified 1844 genes that showed significant differential expression between tumor and normal controls, with a large
number clearly influencing phosphatidylinositol and mitogen-activated protein kinase signaling in PA. Most CNAs
identified in this study were single-clone alterations. However, a small region of loss involving up to seven adjacent
clones at 7q11.23 was observed in seven tumors and correlated with the underexpression of BCL7B. Loss of four
individual clones was also associated with reduced gene expression including SH3GL2 at 9p21.2–p23, BCL7A
(which shares 90% sequence homology with BCL7B) at 12q24.33, DRD1IP at 10q26.3, and TUBG2 and CNTNAP1
at 17q21.31. Moreover, the down-regulation of FOXG1B at 14q12 correlated with loss within the gene promoter
region in most tumors. This is the first study to correlate differential gene expression with CNAs in PA.
Neoplasia (2008) 10, 757–772
Address all correspondence to: Nicola Potter, Queen Square, London, UK. E-mail: n.potter@ion.ucl.ac.uk
1Supplementary data are available at the following links on request to the authors: http://www.ion.ucl.ac.uk/paper_data_np/SupplementaryData.doc, http://www.ion.ucl.ac.uk/
paper_data_np/SupplementaryDataTables5and8.xls.
Received 15 October 2007; Revised 9 May 2008; Accepted 11 May 2008
Copyright © 2008 Neoplasia Press, Inc. All rights reserved 1522-8002/08/$25.00
DOI 10.1593/neo.07914
www.neoplasia.com
Volume 10 Number 8 August 2008 pp. 757–772 757
Introduction
The most prevalent brain tumors in the pediatric population are as-
trocytomas, which most frequently manifest as pilocytic astrocytoma
(PA), World Health Organization (WHO) grade I [1]. Pilocytic as-
trocytomas are commonly located in the cerebellum and can often
be completely surgically resected, resulting in excellent long-term sur-
vival [2]. However, a small number of PA recur after resection and
may occasionally undergo malignant transformation [3].
The genetic events that contribute to the development of PA are
poorly defined. Cytogenetic analysis of pediatric PA has shown that
most of these tumors (>70%) have a normal karyotype. Numerical
and structural abnormalities of chromosomes 5, 6, 7, 8, and 9 have
been reported, although definitive, nonrandom aberrations have
not yet been identified [4–8]. Loss of the p53 locus on chromosome
17p has been reported in some PA studies but not consistently [9–11].
Similarly, although TP53 gene mutations were found in 7 of 20 pedi-
atric PA, other studies have failed to confirm these findings [12,13].
Global expression technology can now generate detailed gene ex-
pression profiles of tumors, and statistical algorithm–based classifica-
tions can be used to identify subgroups with clinical or biologic
significance [14,15]. Array gene expression profiles of 21 pediatric
PA have shown that genes involved in neurogenesis, cell adhesion, syn-
aptic transmission, central nervous system development, potassium
ion transport, protein dephosphorylation, and cell differentiation
were significantly deregulated. The same study also demonstrated
that the tumors clustered into two groups could be distinguished
by the extent of myelin basic protein staining [16]. A similar ap-
proach has also been used to identify an expression signature that
can stratify PA according to tumor location. A signature of 36 genes
showed differential expression between supratentorial PA and those
arising in the posterior fossa [17].
Array-based comparative genomic hybridization (aCGH) has re-
cently been used to define genome-wide aberrations at a resolution
of 1 Mb in adult malignant astrocytoma [18–24]. Only one previous
study has used array technology to investigate chromosome copy
number aberrations (CNAs) in PA [25]. Whole-chromosome aber-
rations were only observed in tumors arising in patients older than
10 years, in which the most common aberrations were gain of chro-
mosomes 5 and 7, present in 13% and 17% of cases, respectively.
Whole-chromosome aberrations of chromosome 15 were present in
6% of cases and of chromosomes 4, 6, 9, 10, 11, 12, and 20 in 3%
of cases [25]. Single-nucleotide polymorphic allelic arrays have also
been used to identify regions of allelic imbalance in low-grade pedi-
atric gliomas including six PA. No detectable loss of heterozygosity
was found at any of the 11,562 single-nucleotide polymorphic loci
investigated in the PA [26]. It is also possible that epigenetic events
such as aberrant promoter hypermethylation are common genomic
alterations in pediatric low-grade astrocytoma and that they may have
a greater impact on tumor development [27].
The aim of the present study was to correlate aberrant gene expres-
sion in pediatric PA with CNAs or gene promoter hypermethylation
to identify and characterize cellular pathways that are involved in tumor
development and growth. We have used the Affymetrix GeneChip
HG_U133A (Affymetrix, Santa Clara, CA) to generate gene expres-
sion profiles and to identify aberrantly expressed genes in 19 pediat-
ric PA biopsies. In 11 of 19 cases, we also identified CNAs using the
aCGH SpectralChip 2600 (Spectral Genomics, Houston, TX). Both
approaches were validated by real-time quantitative polymerase chain
reaction (RT-QPCR). The methylation status of the promoter re-
gions of six genes, showing significant underexpression in the PA com-
pared to the normal controls, was examined using methylation-specific
PCR (MSP) and bisulfite sequencing to investigate alternative mech-
anisms of transcriptional silencing in PA. These genes have previously
been reported as being methylated in astrocytoma or in other tumors
or cancer [28–33].
Materials and Methods
Tumor Samples and RNA Preparation
Pilocytic astrocytoma tumor tissue was obtained with informed
consent from 19 pediatric patients directly from the operating theater
and was stored in liquid nitrogen until ready for use. All tumor
samples were directly adjacent to tumor tissue processed for routine
histologic evaluation and were first examined macroscopically to en-
sure that no frankly normal tissue was present. They were diagnosed
according to the WHO classification and were reviewed by two neuro-
pathologists [1]. The patients’ mean age at diagnosis was 5.8 years
(range, 1.75–11.5 years), with a female/male ratio of 8:11. At the
time of this study, patient follow-up was available from diagnosis for
17 children who remain alive (follow-up ranged from 1 to 160 months
from diagnosis; Table W1).
Total RNA was isolated from the 19 tumor samples using TRIzol
reagent (Invitrogen Ltd, Paisley, UK) followed by cleanup using an
RNeasy mini spin column (Qiagen, Crawley, UK). The quality and
quantity of each sample were assessed using the Agilent 2100 Bio-
analyser (Agilent Technologies Ltd, West Lothian, UK). Control
RNA, consisting of four pooled normal whole-brain total RNA sam-
ples from young adults between 21 and 29 years of age, were ob-
tained from AMS Biotechnology (Abingdon, Oxfordshire, UK) as
previously described by Wong et al. [16].
cRNA Synthesis, Array Hybridization, and Array Scanning
Total RNA from 19 PA and 4 pooled normal whole-brain sam-
ples was used to prepare biotinylated target RNA following the manu-
facturer’s instructions (Affymetrix). Briefly, 8 μg of total RNA was
used to generate first-strand cDNA using a T7-linked oligo (dT)
primer. Second-stand synthesis was then completed followed by a
final transcription step with biotinylated UTP and CTP to label
and amplify cRNA. The labeled cRNA was hybridized overnight
to the HG_U133A array (Affymetrix). The arrays were washed
and stained with streptavidin–phycoerythrin and were scanned using
an Affymetrix GeneChip Scanner 3000. Array background, Q values,
and mean intensities were within acceptable ranges for all arrays.
Affymetrix Array Data Analysis
Analysis was carried out using GeneSpring version 7.2 (Silicon
Genetics, Redwood City, CA). The samples were analyzed in one ex-
periment, and data transformation normalization was completed.
Measurements less than 0.01 (set as a standard cutoff ) were read-
justed to 0.01, and per-chip normalizations were completed dividing
all measurements on each array by the 50th percentile. The resulting
expression levels were centered on 1 for each chip. The experiment
was then normalized to the control samples (per gene normalization).
Identification of Aberrantly Expressed Genes
Data filters were applied after the raw expression data had been nor-
malized, to remove unreliable and unnecessary data from further analy-
sis including genes that were constant in both control and tumor
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samples and Affymetrix standard control genes. Unsupervised hierarchi-
cal clustering with the remaining 10,653 informative probe sets was
used to cluster the tumors according to gene expression profile similarity.
A t test and Bonferroni multiple correction test (P < .05) were used to
identify genes that showed a significant difference in expression between
PA and normal controls. The variance statistic was derived from the
multiple samples in each condition. A filter tool was then used to iden-
tify genes that showed a greater than twofold change in expression be-
tween the two conditions. From the 10,653 reliable expression results,
2273 probe sets that showed a significant and greater than twofold
change in expression between PA and control samples, as described by
Sowar et al. [34], were identified. These represented 1844 specific genes
that were used for further analysis byOnto-Tools [35,36]. This software
generates functional profiles of differentially expressed genes and assesses
the impact of their alterations on biologic processes and pathways. The
pathways used byOnto-Tools originate from the Kyoto Encyclopedia of
Genes and Genomes (KEGG) database [37].
Validation of Differential Gene Expression by
RT-QPCR Analysis
Real-time quantitative polymerase chain reaction analysis was
completed for six genes that showed a twofold and significant differ-
ence in expression between PA and normal controls to validate the
Affymetrix array results. RNA was available for RT-QPCR analysis
from 16 of 19 tumors and 4 normal controls. cDNA was synthesized
from 1 μg of total RNA using the QuantiTect Reverse Transcription
Kit (Qiagen) following the manufacturer’s instructions. Gene-specific
oligonucleotide probes and primer pairs were obtained from Assays
on Demand (Applied Biosystems, Warrington, UK) for CCNA1,
SPINT2, MAPK1, MATK, TIMP1, and MCL1. All probes were de-
signed across exon–exon boundaries. The TaqMan Universal PCR
Master Mix No AmpErase UNG was used in a 25-μl reaction vol-
ume after cycling conditions recommended by the manufacturer.
β-Actin was used as an endogenous control. All reactions were com-
pleted as single-well triplicates using the ABI Prism 7000 Sequence
Detection System. No-template and no-amplification controls were
included in each experiment. The comparative CT method (PE Ap-
plied Biosystems, Warrington, UK) was used to determine the rela-
tive ratio of expression for each gene.
DNA Preparation and aCGH
Tumor tissue was available for aCGH analysis from 11 of 19 PA.
Genomic DNA was isolated from the same tissue mass as total RNA
usingDNAMiniKit following themanufacturer’s instructions (Qiagen).
Array-based comparative genomic hybridization was carried out using
the SpectralChip 2600 following manufacturer’s instructions (Spec-
tral Genomics). The SpectralChip 2600 is a human BAC array that
generates genome-wide molecular profiles at a resolution of 1 Mb al-
lowing quantitative analysis. Each of the 2600 complementary BAC
elements are printed on a glass slide, fluorescent-labeled normal and
tumor DNA are cohybridized to the array, and dye ratios are calcu-
lated for each clone. Briefly, 1 μg of tumor and pooled sex-mismatched
reference DNA (Promega, Southampton, UK) were differentially la-
beled with Cy5-dCTPorCy3-dCTPusing randomprime labeling (Bio-
prime Labeling Kit; Invitrogen). Labeled tumor and reference DNA
were cohybridized to the SpectralChip at 37°C for 16 hours in a hybridi-
zation chamber (Corning, Inc., Corning, NY). Arrays were washed at
50°C for 20 minutes in 50% formamide/2× SSC followed by 2× SSC/
0.1% Tween 20 for 20 minutes and 0.2× SSC for 10 minutes. Arrays
were then washed in 80% ethanol and blown dry using nitrogen gas.
Finally, the arrays were scanned using a microarray scanner (GenePix
Personal 4100A;Molecular Devices, CA). Each experiment was dupli-
cated swapping the dye labels between tumor and reference DNA.
Array-Based Comparative Genomic Hybridization Analysis
The scanned images were analyzed using GenePix Pro 6 software
(Molecular Devices). Image spots were defined by an automatic grid
feature that correlates the BAC clone position on the array with clone
details including genomic locations. The spots were adjusted where
necessary, and the dye intensities were calculated. Further analysis
was completed using Formatter Software (Digital Scientific, Cam-
bridge, UK; MIDAS Team) [38]. Preliminary analysis involved the
removal of defective spots, that is, those without a signal, and back-
ground corrections were applied. A flip-dye consistency check involv-
ing the cross-log ratios of each signal from the duplicated clone spots
on each array and from the dye swap experiment was also completed,
and those signals that showed a greater than ±2SD variation between
replicates were discarded [39,40].
Iterative linear regression global normalizations were completed
for each sample reducing the SD of spot log2 ratios. In this approach,
the SD of a given sample was continuously recalculated, removing
outliers, until the correlation coefficients converged to a constant
value. The final value is referred to as the modified SD (MSD).
The outlier range used for this was ±2SD [41]. Those clones that
showed a log2 ratio in excess of 3MSD were deemed as gained or
lost. This approach assumes that data variations are random, and
constant nonchanging results form most data. Theoretically, only
0.7% of data values will occur outside the threshold; therefore, any
deviations exceeding 3SD are considered true positives [39,40].
Validation of DNA Copy Number by RT-QPCR Analysis
To validate the SpectralChip 2600 array experiments, RT-QPCR
analysis to determine relative DNA copy number was completed at
five genomic regions and/or gene loci including 1p36.32, 14q12,
the promoter region of FOXG1B at 14q12, BCL7B at 7q11.23, and
BLC7A at 12q24.33. Primer and oligonucleotide probe sets were de-
signed within gene exon boundaries using primer design Web server
and software packages (http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi) and Primer Express and were purchased from
MWG-Biotech (Milton, Keynes, UK). β-Actin, at 7p12, was used as
an endogenous control because this region was not altered in any of
the PA in this study (see Table W2 for specific primer and probe
sequences and concentrations). Probes for the genes of interest were
labeled with the FAM fluorescent report, and the endogenous control
probe was labeled with VIC. Sufficient DNA was available from 10 of
11 tumors investigated using the SpectralChip 2600 array and 4 addi-
tional tumors, for which expression array analysis had been completed
(IN2356, IN2825, IN2921, and IN3156). DNA extracted from blood
samples of four normal individuals and one pooledmale and one pooled
female DNA samples (Promega) were used as normal reference controls.
The RT-QPCR experiments were carried out using the ABI Prism
7000 Sequence Detection System. Reactions were completed as single-
well triplicates in a final volume of 25 μl consisting of 1× QuantiTect
Probe PCRMix (Qiagen), probe and primers at the required concentra-
tions, and 25 ng of genomic DNA. No-template and no-amplification
controls were also included for each locus investigated. The thermal cy-
cling profile consisted of a 15-minute heat activation step at 95°C, fol-
lowed by 40 cycles at 95°C for 10 seconds and 60°C for 1 minute.
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Before genomic quantification, primer limitation experiments
were carried out to determine optimum primer concentrations for
each experiment (see User Bulletin #2, Applied Biosystems, Warring-
ton, UK). Primer concentrations that generated the highest magni-
tude of signal intensity (ΔRn) but lowest cycle threshold (CT) at a
given threshold were selected. The standard curve method (PE Ap-
plied Biosystems, Warrington, UK) was used to determine the rela-
tive copy number for each locus. A standard curve was included on
each 96-well plate for control and target regions consisting of serially
diluted normal genomic DNA (pooled blood from 20 healthy indi-
viduals). Only standard curves with correlation coefficients of 0.98
and higher were used for genomic copy number analysis. Tumors
with values less than or equal to the copy number of controls minus
the 95% reference range of controls (or 2× SD of controls) were con-
sidered to have genomic loss, whereas a value greater or equal to the
copy number of controls plus 95% reference range of controls (or 2×
SD of controls) was regarded as gain [42,43].
Methylation-Specific PCR and Sequencing
The methylation status of the promoter regions of six genes was
investigated in 17 of 19 PA using MSP. Sequencing was used to con-
firm these results in two tumors and one normal brain control. The
MSP and sequencing primer pairs for this study were either adapted
or designed according to MSP principles [44,45] with the aid of the
CpG island identification Web server (http://www.uscnorris.com/
cpgislands2/), primer design Web server and software packages
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi), and
Primer Express (see Tables W3 and W4 for MSP and sequencing
primer information).
After sodium bisulfite modification of tumor and normal DNA as
described previously, MSP was carried out in a 25-μl volume with
HotStart Taq (Qiagen) [44]. After an initial step of 95°C for 15 min-
utes, DNA was amplified by 35 cycles for 30 seconds at 95°C,
for 30 seconds at the optimal annealing temperature for each primer
pair, and for 30 seconds at 72°C, followed by a final extension step at
72°C for 5 minutes. Polymerase chain reaction analysis for sequencing
was carried out in a 50-μl volume with HotStart Taq (Qiagen). After
a 15-minute incubation at 95°C, DNA was amplified by 38 cycles at
94°C for 15 seconds, optimal annealing temperatures for primer pairs
for 30 seconds and at 72°C for 45 seconds, followed by a final exten-
sion at 72°C for 5 minutes. A blank control containing all MSP com-
ponents except the sample DNA and two positive controls (normal
DNA and universally methylated DNA, both of which were bisulfite-
treated as described previously) was included in each experiment. Pro-
ducts were separated using a 1.5% agarose gel containing ethidium
bromide and 1× Tris-borate-EDTA buffer. The products were visual-
ized by UV light.
Polymerase chain reaction amplifications of DNA for sequencing
were performed using the BigDye Terminator v1.1 cycle sequencing
kit following manufacturer’s instructions (Applied Biosystems, Foster
City, CA). Sequencing was carried out using an ABI 3730×1 DNA
Analyser, and raw data were analyzed with SeqScape software v2.5
(Applied Biosystems, Foster City, CA).
Results
Gene Expression Profiles of Pediatric PA
Using the Affymetrix GeneChip HG_U133A, we have studied
the expression pattern of approximately 22,000 genes in pediatric
PA compared to normal brain (see Table W5 for all Affymetrix
GeneChip raw data). Unsupervised hierarchical clustering using
10,653 reliable gene expression results was used to generate a den-
drogram illustrating the similarity in expression profiles of the 19 PA
(Figure 1). The tumor and normal control samples clustered in-
dependently. However, the PA did not group or order according to
patient age, sex, or tumor location, and no consistent expression pro-
files could be associated with these clinical parameters or patient out-
come. Moreover, no further subgroups were clearly defined, in
contrast to the previous findings [16,17]. Wong et al. [16] described
a molecular signature of 89 genes that distinguished two subgroups
of PA representing tumors with different potentials of progression. A
list of the 89 genes was not available in the literature. However, 16 of
these 89 genes were described by Wong et al. [16] and were involved
in biologic processes that significantly altered between the two sub-
groups. In total, 13 of these 16 genes showed reliable data in the
present study and were used to cluster the 19 PA. The tumors did
not cluster into subgroups, and a continuous increase or decrease in
the expression of these 13 genes was seen between tumors that are
least similar (Figure W1, a and b).
From 10,653 reliable expression results, 1844 genes showed a two-
fold and significant change in expression in PA compared to the
normal controls. Of these, 1002 were up-regulated and 842 were
down-regulated. Genes that showed a greater than 10-fold change
in expression and were either involved in a KEGG pathway or have
been well characterized were investigated further (Table 1). SERPINA3,
a protease inhibitor, showed the largest up-regulation in gene expres-
sion with an 80.89-fold change in the tumors compared to normal
brain. FOXG1B, a member of the forkhead family of transcription
factors, showed the largest down-regulation in gene expression with
a 325.73-fold change.
The Onto-Tools software was used to rank the KEGG pathways
influenced by the 1844 differentially expressed genes according to
the extent of differential gene expression. Of the 53 pathways that
were ranked, only those of interest are displayed in Table 2 (see
Table W6 for all pathways involved in this analysis). The pathway
most affected by differential gene expression (rank 1) was antigen
processing and presentation, in which most genes are significantly
up-regulated and located at 6p21.3.
To investigate if particular differentially expressed genes could in-
fluence several pathways and have an overall impact on tumor de-
velopment, those genes involved in five or more pathways were
identified (Table 3). Although MAPK1 is involved in 17 pathways,
this gene only showed a 2.01-fold down-regulation in expression. In
contrast, genes with the largest fold changes are involved in fewer
pathways. Only two genes, CAMK2A and PRKCB1, showed a greater
than 10-fold change in expression and are involved in more than five
pathways (Tables 1 and 3), suggesting that those genes with the high-
est degree of disregulation in pediatric PA may not have the greatest
impact on cellular pathways.
Validation of Differential Gene Expression by
RT-QPCR Analysis
To validate the expression results obtained from the Affymetrix
array experiments, the expression of six genes that showed a two-
fold and significant difference in expression in PA compared to
the normal controls was assessed using RT-QPCR. The array data
demonstrated that CCNA1, SPINT2, MAPK1, and MATK were
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significantly down-regulated and TIMP1 and MCL1 were signifi-
cantly up-regulated. Real-time quantitative polymerase chain reac-
tion confirmed these changes in gene expression in PA compared
to normal brain (Table W7).
Genomic Aberrations Found in Pediatric PA
Array-based comparative genomic hybridization was carried out
using the SpectralChip 2600 to identify regions of chromosome gain
and loss in 11 pediatric PA. The array profile from the most altered
tumor, IN2368, is illustrated in Figure 2. In total, 97 individual BAC
clones were found to be either gained or lost in one or more tumors.
Of these, 26 were gained, 64 were lost, and 7 were either gained or
lost in different tumors (Figure 3; see Table W8, a–l, for details of
these 97 altered clones and the combined dye swap raw data for each
sample). Several chromosome regions were frequently altered in PA.
BAC clones mapping to 1p36.32, 14q12, 19p13.2, and 22q13.33
showed gain, loss, or both in 91%, 82%, 64%, and 91% of tumors,
respectively. Other regions less frequently altered included the follow-
ing: 7q11.2 and 8q21 in 45% of tumors; 7q34, 8q24.3, 10q21.3,
Figure 1. Unsupervised hierarchical clustering of 19 pediatric PA and 4 normal brain controls using 10,653 reliable gene expression
results. The dendrogram color saturation is proportional to the magnitude of the difference from the mean, ranging from red (over-
expressed) to green (underexpressed). Patient ages are in years at diagnosis. Tumor labels in green indicate a male patient, and pink
a female patient. CERE indicates cerebellum; CHI, chiasmatic; OP, optic pathway; PF, posterior fossa.
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and 17q21 in 36% of tumors; and 6q12, 6q13, 17q21.3, and
19p13.3 in 27% of tumors. A small region containing two adjacent
clones at 1p13 was lost in one tumor and a region that varied in size
containing up to seven adjacent clones at 7q11.23 was lost in seven
tumors. Large-scale copy number variants (LCVs) in specific chro-
mosome regions have been characterized in the normal population.
Of 97 clones altered in PA of this study, 37 are located in regions of
known LCV (Figure 3).
Table 1. Differentially Expressed Genes That Show a 10-Fold Minimum Change in Expression from the Normal and Are Involved in Specific Pathways or Are Well Characterized with Functions That
Can Be Linked to Tumor Development.
Rank Gene Symbol Gene Description Fold Change in Expression Chromosome Location
1 SERPINA3 Serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase,
antitrypsin), member 3
80.89 14q32.1
2 CHI3L1 Chitinase 3-like 1 (cartilage glycoprotein-39) 56.98 1q32.1
4 CHAD 2 (4, 11) Chondroadherin 43.68 17q21.33
6 TIMP4 Tissue inhibitor of metalloproteinase 4 41.47 3p25
7 WEE1 1 (38) WEE1 homolog (Schizosaccharomyces pombe) 41.03 11p15.3–p15.1
11 T1A-2 Lung type-I cell membrane–associated glycoprotein 35.21 1p36
12 ABCC3 ATP-binding cassette, subfamily C (CFTR/MRP), member 3 33.72 17q22
15 IL1RAP 2 (1, 47) Interleukin 1 receptor accessory protein 26.58 3q28
17 CSPG4 Chondroitin sulfate proteoglycan 4 (melanoma-associated) 23.77 15q23
19 AGTRL1 1 (32) Angiotensin II receptor–like 1 22.36 11q12
22 CD44 Homo sapiens CD44 isoform RC (CD44) mRNA, complete cds 19.88 11p13
24 MYT1 Myelin transcription factor 1 18.49 20q13.33
26 TAZ Transcriptional coactivator with PDZ-binding motif (TAZ) 17.53 3q23–q24
31 TIMP1 Tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity,
collagenase inhibitor)
16.23 Xp11.3–p11.23
32 HLA-DPA1 3 (1, 2, 32) Major histocompatibility complex, class II, DP alpha 1 15.79 6p21.3
36 S100A10 S100 calcium binding protein A10 (annexin II ligand, calpactin I,
light polypeptide (p11))
15.27 1q21
38 TLR2 1 (14) Toll-like receptor 2 14.66 4q32
40 TFPI 1 (12) ESTs, weakly similar to cytokine receptor-like factor 2;
cytokine receptor CRL2 precusor (Homo sapiens)
14.09 2q32
44 POSTN Osteoblast-specific factor 2 (fasciclin I-like) 12.60 13q13.1
46 CHI3L2 Chitinase 3-like 2 12.22 1p13.3
48 CCL3 Chemokine (C–C motif ) ligand 3 11.89 17q11–q21
49 MSR1 Macrophage scavenger receptor 1 11.87 8p22
50 SRPX Sushi-repeat–containing protein, X chromosome 11.29 Xp21.1
51 CSPG2 1 (2) Chondroitin sulfate proteoglycan 2 (versican) 10.86 5q14.3
56 CD151 CD151 antigen 10.61 11p15.5
−74 FGF13 2 (5, 6) Fibroblast growth factor 13 −10.34 Xq26.3
−72 MEF2C 1 (5) MADS box transcription enhancer factor 2, polypeptide C
(myocyte enhancer factor 2C)
−10.48 5q14
−70 WNT10B 2 (28, 46) wingless-type MMTV integration site family, member 10B −10.50 12q13
−69 NPY1R 1 (32) Neuropeptide Y receptor Y1 −10.96 4q31.3–q32
−67 ATP2B2 1 (19) Homo sapiens, similar to nuclear localization signals binding protein 1,
clone IMAGE:4933343, mRNA
−11.22 3p25.3
−66 PRKCB1 15 (3–5, 7, 8, 10, 16–19,
22, 28, 36, 39, 41)
Protein kinase C, beta 1 −11.24 16p11.2
−65 MAL mal, T-cell differentiation protein −11.55 2cen-q13
−62 CACNA2D3 1 (5) Calcium channel, voltage-dependent, alpha 2/delta 3 subunit −11.89 3p21.1
−60 GRIN1 3 (7, 19, 32) Glutamate receptor, ionotropic, N -methyl D-aspartate 1 −12.15 9q34.3
−59 HTR2A 3 (10, 19, 32) 5-Hydroxytryptamine (serotonin) receptor 2A −12.22 13q14–q21
−55 SNAP25 1 (43) Synaptosomal-associated protein, 25 kDa −13.04 20p12–p11.2
−54 PTK2B 4 (8, 16, 17, 19) PTK2B protein tyrosine kinase 2 beta −13.42 8p21.1
−52 VIP 1 (32) Vasoactive intestinal peptide −14.27 6q26–q27
−50 VAMP1 1 (43) Vesicle-associated membrane protein 1 (synaptobrevin 1) −15.17 12p
−48 NPY 2 (32, 35) Neuropeptide Y −15.63 7p15.1
−45 ENPP2 Ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin) −17.09 8q24.1
−44 MBP Myelin basic protein −17.48 18q23
−39 HTR2C 3 (10, 1, 32) 5-Hydroxytryptamine (serotonin) receptor 2C −19.23 Xq24
−37 P2RX5 2 (19, 23) Purinergic receptor P2X, ligand-gated ion channel, 5 −19.57 17p13
−32 MATK 2 (6, 15) Megakaryocyte-associated tyrosine kinase −23.75 19p13.3
−31 CRH 2 (22, 32) Corticotropin-releasing hormone −24.27 8q13
−22 NEFH 2 (25, 31) Neurofilament, heavy polypeptide 200 kDa −27.40 22q12.2
−21 ICAM5 Intercellular adhesion molecule 5, telencephalin −27.70 19p13.2
−19 EGR4 Early growth response 4 −28.90 2p13
−15 CAMK2A 5 (7, 8, 19, 20, 28) Calcium/calmodulin–dependent protein kinase (CaM kinase) II alpha −36.76 5q33.1
−13 ATP2B2 1 (19) ATPase, Ca2+ transporting, plasma membrane 2 −39.22 3p26–p25
−11 SST 1 (32) Somatostatin −43.86 3q28
−10 ITPKA 2 (3, 19) Inositol 1,4,5-trisphosphate 3-kinase A −49.50 15q14–q21
−6 GABRA5 1 (32) γ-Aminobutyric acid (GABA) A receptor, alpha 5 −101.01 15q11.2–q12
−3 CACNG3 1 (5) Calcium channel, voltage-dependent, gamma subunit 3 −136.99 16p12–p13.1
−2 CCK 1 (32) Cholecystokinin −146.63 3p22–p21.3
−1 FOXG1B Forkhead box G1B −325.73 14q12–q13
The number of pathways that each gene is involved in is given in bold after the gene symbol. The numbers inside the parentheses correspond to the specific pathways in Table 2. Genes highlighted in red
are involved in multiple pathways listed in Table 3.
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Validation of DNA Copy Number by RT-QPCR Analysis
To validate the results obtained from the SpectralChip 2600 array,
RT-QPCR analysis was used to determine the relative genomic copy
number at five genomic regions and/or gene loci (see Table W9 for
standard curve method raw data). This approach confirmed CNAs
(both loss and gain) of the BAC clone RP4-703E10 at 1p36.32 in
80% of cases (Tables 4 and 5). Loss of BLC7A at 12q24.33 was ver-
ified by RT-QPCR in the single tumor, which demonstrated loss of
the equivalent BAC clone (RP11-87C12), and in 11 additional tu-
mors, indicating the superior sensitivity of RT-QPCR analysis in the
detection of small CNAs [46]. BCL7B lies within a small deletion of
up to seven adjacent clones at 7q11.23. Real-time quantitative poly-
merase chain reaction analysis confirmed loss of this gene in five of
six tumors and detected loss in seven additional cases. Loss of clone
RP11-125A5 in the region of LCV at 14q12 was verified by RT-
QPCR analysis in only two of eight tumors demonstrating loss by
BAC array analysis, similar to the findings of the recent study by
Qiao et al. [47].
Correlation of Genomic and Expression Array Data
Reliable gene expression data were not available for all genes lo-
cated in the same regions as the 97 BAC clones which were lost
and/or gained. Overall, loss of four single clones correlated with
down-regulation of genes mapping to the same region. These com-
prised SH3GL2 at 9p21.2–p23 (clone lost in one tumor), DRD1IP
at 10q26.3 (clone lost in one tumor), BCL7A at 12q24.33 (clone lost
in one tumor), and TUBG2 and CNTNAP1 at 17q21.31 (clone lost
in two tumors). In seven tumors, there was also loss of a region at
7q11.23 containing up to seven adjacent clones that mapped to
71,658,093–73,945,118 (Figure 4). This region contains 47 genes
in total, but only 17 were present on the Affymetrix GeneChip
HG_U133A. Of these genes, seven showed unreliable expression
data, nine were expressed at a normal level, and BCL7B was signifi-
cantly down-regulated in all tumors compared to normal controls
(P < .05). In addition, FOXG1B maps adjacent to the clone RP11-
125A5 at 14q12, which was determined to be lost by aCGH and
showed significant down-regulation in all PA compared to normal
controls (P < .01). Real-time quantitative polymerase chain reaction
analysis of relative DNA copy number of the FOXG1B promoter
demonstrated genomic loss in 8 of 14 tumors.
Critically, although clone loss at these regions was not seen in every
tumor, all samples showed a twofold and significant down-regulation
in the specific genes at these loci listed in Table 6. No correlations were
found between clone gain and gene overexpression.
Methylation-Specific PCR and Sequencing
Methylation-specific PCR products were only generated by primer
sets specific for unmethylated promoter regions, indicating that the
promoter regions ofCDKN1C, PRDM2, SPINT2,REPRIMO,CCNA1,
and DAPK1 were not methylated in the 17 PA analyzed. Sequencing
of each gene in IN3115 and IN2940 and normal brain confirmed
that promoter region methylation was not present in either PA or
Table 2. The Pathway Express Results Ranking the KEGG Pathways Incorporating the 1844 Differentially Expressed Genes in PA.
Rank Unique Pathway ID KEGG Database Pathway Name Impact Factor Genes in Pathway Pathway Genes in Input (%)
1 1:04612 Antigen processing and presentation 76.6 86 24.4
2 1:04514 Cell adhesion molecules (CAMs) 24.1 132 25.8
3 1:04070 Phosphatidylinositol signaling system 23.2 79 27.8
4 1:04510 Focal adhesion 14.7 194 25.8
5 1:04010 MAPK signaling pathway 14.3 273 22.7
6 1:04810 Regulation of actin cytoskeleton 12.9 206 23.3
9 1:04210 Apoptosis 9.3 84 27.4
10 1:04540 Gap junction 9.3 99 25.3
11 1:04512 ECM–receptor interaction 9.1 87 26.4
12 1:04610 Complement and coagulation cascades 8.8 69 27.5
14 1:04620 Toll-like receptor signaling pathway 8.1 91 25.3
16 1:04670 Leukocyte transendothelial migration 7.8 117 23.1
17 1:04650 Natural killer cell mediated cytotoxicity 7.3 128 21.1
18 1:04662 B-cell receptor signaling pathway 7.2 63 27.0
19 1:04020 Calcium signaling pathway 7.0 176 18.2
24 1:04910 Insulin signaling pathway 5.7 135 20.7
25 1:01510 Neurodegenerative disorders 5.7 35 28.6
26 1:05210 Colorectal cancer 5.6 77 23.4
28 1:04310 Wnt signaling pathway 5.5 147 18.4
32 1:04080 Neuroactive ligand–receptor interaction 4.7 302 11.3
33 1:04660 T cell receptor signaling pathway 4.4 93 20.4
35 1:04920 Adipocytokine signaling pathway 4.0 69 20.3
36 1:04530 Tight junction 3.9 119 16.8
37 1:04520 Adherens junction 3.8 77 20.8
38 1:04110 Cell cycle 3.5 112 16.1
39 1:04370 Vascular endothelial growth factor (VEGF) signaling pathway 3.0 72 16.7
42 1:04150 mTOR signaling pathway 2.6 49 18.4
43 1:04130 SNARE interactions in vesicular transport 2.5 36 13.9
44 1:04350 TGFβ signaling pathway 2.3 84 15.5
45 1:04630 Jak–STAT signaling pathway 2.2 153 13.7
46 1:04340 Hedgehog signaling pathway 1.6 57 12.3
47 1:04060 Cytokine–cytokine receptor interaction 1.6 256 11.7
51 1:04140 Regulation of autophagy 0.8 29 3.4
52 1:04330 Notch signaling pathway 0.8 46 8.7
The pathways are ranked according to impact factor, taking into account the fold change, the number of genes disrupted in a pathway, and the influence each gene exerts on a pathway.
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Table 3. The Pathway Express Results of Differentially Expressed Genes Involved in ≥5 Pathways.
Gene Symbol Gene Description Fold Change in Expression Number of Pathways Gene Involved in Chromosome Location
MAPK1 Mitogen-activated protein kinase 1 −2.01 17 (4–8, 10, 17, 21, 22, 24, 26, 37, 39–42, 44) 22q11.21
PIK3CB Phosphoinositide-3-kinase, catalytic, beta polypeptide −2.05 16 (3, 4, 6, 9, 14, 16–18, 24, 26, 33, 39–42, 45) 3q22.3
PIK3R1 Phosphoinositide-3-kinase, regulatory
subunit 1 (p85 alpha)
−2.13 16 (3, 4, 6, 9, 14, 16–18, 24, 26, 33, 39–42, 45) 5q13.1
PRKCB1 Protein kinase C, beta 1 −11.24 15 (3–5, 7, 8, 10, 16–19, 22, 28, 36, 39, 41) 16p11.2
AKT3 v-akt murine thymoma viral oncogene
homolog 3 (protein kinase B, gamma)
−2.54 14 (4, 5, 9, 14, 18, 24, 26, 33, 35, 36, 39, 41, 42, 45) 1q43–q44
MAP2K1 Mitogen-activated protein kinase kinase 1 −4.17 12 (4–8, 10, 17, 22, 24, 26, 39, 41) 15q22.1–q22.33
MAPK9 Mitogen-activated protein kinase 9 −3.48 11 (4, 5, 8, 14, 15, 24, 26, 28, 35, 40, 41) 5q35
MAPK10 Mitogen-activated protein kinase 10 −2.28 11 (4, 5, 8, 14, 15, 24, 26, 28, 35, 40, 41) 4q22.1–q23
PRKACB Protein kinase, cAMP-dependent, catalytic, beta −2.55 11 (5, 7–10, 19, 20, 24, 28, 46, 48) 1p36.1
PPP3CA Protein phosphatase 3 (formerly 2B), catalytic
subunit, alpha isoform (calcineurin A alpha)
−4.13 11 (5, 7, 9, 17–19, 21, 28, 31, 33, 39) 4q21–q24
PPP3CB Protein phosphatase 3 (formerly 2B), catalytic
subunit, beta isoform (calcineurin A beta)
−3.65 10 (5, 7, 9, 17–19, 21, 28, 31, 33, 39) 10q21–q22
PRKX Protein kinase, X-linked 2.08 10 (5, 7, 8, 10, 19, 20, 24, 28, 46, 48) Xp22.3
PPP3R1 Protein phosphatase 3 (formerly 2B), regulatory
subunit B, 19 kDa, alpha isoform
(calcineurin B, type I)
−3.05 10 (5, 7, 9, 17–19, 21, 28, 33, 39) 2p15
IKBKB Inhibitor of kappa light polypeptide gene
enhancer in B cells, kinase beta
2.75 9 (5, 9, 14, 15, 18, 24, 33, 35, 40) 8p11.2
JUN v-jun sarcoma virus 17 oncogene homolog (avian) 2.49 9 (4, 5, 8, 14, 15, 18, 26, 28, 33) 1p32–p31
PAK1 p21/Cdc42/Rac1–activated kinase 1
(STE20 homolog, yeast)
−7.87 7 (4–6, 15, 17, 21, 33) 11q13–q14
TP53 Tumor protein p53 (Li-Fraumeni syndrome) 3.14 7 (5, 9, 26, 28, 29, 31, 38) 17p13.1
PLCB1 Phospholipase C, beta 1
(phosphoinositide-specific)
−2.73 7 (3, 7, 8, , 10, 19, 22, 28) 20p12
CALM1 Calmodulin 1 (phosphorylase kinase, delta) −2.22 7 (3, 7, 8, 19, 20, 24, 29) 14q24–q31
PDGFRA Platelet-derived growth factor receptor,
alpha polypeptide
5.76 7 (4–6, 10, 19, 26, 47) 4q11–q13
CALM3 Calmodulin 3 (phosphorylase kinase, delta) −2.31 7 (3, 7, 8, 19, 20, 24, 29) 19q13.2–q13.3
ITGB1 Integrin, beta 1 (fibronectin receptor, beta
polypeptide, antigen CD29 includes
MDF2, MSK12)
2.26 6 (2, 4, 6, 11, 16, 21) 10p11.2
ITPR1 Inositol 1,4,5-triphosphate receptor, type 1 −8.62 6 (3, 7, 8, 10, 19, 22) 3p26–p25
ITPR2 Inositol 1,4,5-triphosphate receptor, type 2 5.42 6 (3, 7, 8, 10, 19, 22) 12p11
ROCK1 Rho-associated, coiled-coil containing
protein kinase 1
2.42 6 (4, 6, 16, 21, 28, 44) 18q11.1
NFKBIA Nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, alpha
2.17 6 (9, 14, 15, 18, 33, 35) 14q13
ROCK2 Rho-associated, coiled-coil containing protein
kinase 2
−2.40 6 (4, 6, 16, 21, 28, 44) 2p24
CCND1 Cyclin D1 3.77 5 (4, 26, 28, 38, 45) 11q13
CAMK2A Calcium/calmodulin–dependent protein kinase
(CaM kinase) II alpha
−36.77 5 (7, 8, 19, 20, 28) 5q33.1
CAMK2B Calcium/calmodulin–dependent protein kinase
(CaM kinase) II beta
−8.77 5 (7, 8, 19, 20, 28) 7p14.3–p14.1
GNAI3 Guanine nucleotide binding protein (G protein),
alpha inhibiting activity polypeptide 3
2.72 5 (10, 16, 21, 22, 36) 3p21
TGFB1 Transforming growth factor, beta 1
(Camurati–Engelmann disease)
2.32 5 (5, 26, 38, 44, 47) 19q13.1
ACTN1 Actinin, alpha 1 2.26 5 (4, 6, 16, 36, 37) 14q22–q24
PAK2 p21 (CDKN1A)–activated kinase 2 2.23 5 (4–6, 21, 33) 3q29
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 5.10 5 (5, 14, 18, 26, 33) 14q24.3
ACTN2 Actinin, alpha 2 −2.52 5 (4, 6, 16, 36, 37) 1q42–q43
MAP2K4 Mitogen-activated protein kinase kinase 4 −3.30 5 (5, 8, 14, 15, 41) 17p11.2
PLA2G6 Phospholipase A2, group VI (cytosolic,
calcium-independent)
−2.02 5 (5, 8, 2, 39, 41) 22q13.1
PTPN6 Protein tyrosine phosphatase, nonreceptor type 6 2.21 5 (17, 18, 33, 37, 45) 12p13
FAS Fas (TNF receptor superfamily, member 6) 5.90 5 (5, 9, 13, 17, 47) 10q24.1
CCND2 Cyclin D2 2.02 5 (4, 26, 28, 38, 45) 12p13
PLA2G12A Phospholipase A2, group XIIA 3.99 5 (5, 8, 22, 39, 41) 4q25
GNAS GNAS complex locus −4.93 5 (8, 10, 19, 22, 48) 20q13.3
GNAI1 Guanine nucleotide binding protein (G protein),
alpha inhibiting activity polypeptide 1
−2.25 5 (10, 16, 21, 22, 36) 7q21
CAMK2G Calcium/calmodulin–dependent protein kinase
(CaM kinase) II gamma
−3.40 5 (7, 8, 19, 20, 28) 10q22
The numbers inside the parentheses correspond to the specific pathways in Table 2. Genes highlighted in red are also shown in Table 1.
764 Genetic Aberrations in Pediatric Pilocytic Astrocytoma Potter et al. Neoplasia Vol. 10, No. 8, 2008
the normal samples (see FigureW2, a and b, for gel electrophoresis and
sequencing results).
Discussion
This investigation has focused on the correlation between genomic
CNAs at a 1-Mb resolution and global differential gene expression
in PA. Overall, these data remain descriptive with the aims of iden-
tifying novel candidate target genes and characterizing cellular path-
ways that are involved in tumor development and growth. Future
functional studies are needed to evaluate these targets in pediatric
PA, but as discussed, evidence supports a role for these candidates
in tumorigenesis.
Subgroups and Molecular Signatures in Pediatric PA
Unsupervised hierarchical clustering of PA in this study grouped
tumor and control samples separately but further subgroups within
PA were not identified. Wong et al. [16] previously demonstrated
that two subgroups of PA could be distinguished by a molecular sig-
nature and suggested that these subgroups represented PA with dif-
ferent potentials of progression. Although it has been documented
that pediatric PA that undergo partial excision may reoccur in the
same location, malignant progression is rare [3,48]. In the PA included
in our study, 13 of 89 genes from the molecular signature for which
there were reliable data showed a continuous change in expression
rather than a significant differential expression between two PA sub-
groups. However, the authors recognize that only a proportion of the
genes could be investigated here in a smaller sample group compared
to that of Wong et al. [16]. Sharma et al. [17] also reported a mo-
lecular signature of 36 genes with differential expression between su-
pratentorial PA and posterior fossa PA and suggested that glial tumors
have an intrinsic, lineage-specific signature that reflects the region of
the brain from which the nonmalignant tumor cell precursors orig-
inated. In the present tumor group, most tumors were located in the
posterior fossa and, consequently, a comparison was not possible.
The characterization of molecular signatures that can distinguish PA
arising in different locations or tumor subgroups emphasizes the intrin-
sic genetic heterogeneity of PA and the need for large sample numbers
to identify valid subgroups with clinical or prognostic relevance.
Control Samples in Pediatric PA Microarray Analysis
The use of various controls to identify differentially expressed
genes between normal and diseased samples in microarray experi-
ments can directly influence those genes deemed to show differential
gene expression, as reported by Zorn et al. [49] who investigated the
choice of normal controls in the study of ovarian carcinoma. The
normal controls used in previous microarray studies of brain tumors
vary greatly. Studies comparing tumor expression profiles to normal
brain have used total RNA from tissue samples obtained from nor-
mal brain regions including tissue from a lobectomy after edema,
hippocampus tissue from a patient with epilepsy, subcortical white
matter, cortical brain, the cortex of temporal lobe, and postmortem
cortex, and medulla tissues [50–54]. Groups who have not had direct
access to normal brain have also commercially purchased total RNA
samples of adult and fetal normal brain for use as controls, including
Wong et al. [16,50].
The control samples of this study are pooled adult normal whole-
brain samples from a commercial source. This removes the chance of
tumor contamination within the normal sample and using pooled
normal samples reduces expression variations present in each indi-
vidual. The decision to use adult normal total brain as a control
was reached after detailed investigations of both fetal and adult brain
from specific brain regions and whole brain (Figure W3).
Figure 2. Combined dye swap aCGH profile for the tumor with the most aberrations, IN2368. Iterative linear regression global normali-
zations were used to reduce the SD of spot log2 ratios with an outlier range of ±2SD. Clones that showed a log2 ratio in excess of ±3SD
were deemed to be gained or lost (indicated by the red dotted line).
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Figure 3. Results of aCGH analysis illustrating regions of chromosome gain and loss in pediatric PA. Circles to the right of each chro-
mosome ideogram show the number of individual tumors with copy gains (red) and losses (blue) for each clone among the 11 PA
studied. Clones in a region of copy number variation in the normal population are indicated by a green ring. Adjacent clones lost in
the same tumor are indicated by a yellow box. Multiple clones in a region are indicated by two arrows. Correlations between clone
CNAs and differential gene expression in the same region are indicated by a purple box.
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Hierarchical clustering of adult and fetal normal controls indepen-
dently of the tumors suggested that either fetal or adult normal con-
trols were suitable for the study of tumor biopsy samples. Furthermore,
1345 common differentially expressed probe sets were identified in
the PA when using either adult or fetal normal controls. However, it
was noted that fetal brain is in an exponential or linear growth phase
and that this may affect gene expression and signaling pathways,
masking aspects of the tumor profile if used as a control [55]. In-
creased proliferation, cell signaling, and reduced apoptosis are associ-
ated with fetal development and are characteristics of tumor cells.
Furthermore, on investigation of the cellular pathways influenced
by differential gene expression in the PA when adult or fetal normal
controls were used and in the normal fetal controls when compared
to adult normal controls, it became apparent that genes of the Wnt
signaling pathway, cell cycle, and, to a lesser extent, the colorectal
cancer pathway were up-regulated in the fetal normal controls com-
pared to the adult normal controls and masked some differential gene
expression in the PA. Moreover, the Wnt signaling pathway has been
implicated in fetal development [56–60].
Variation was also seen between the expression profiles of total
brain, cerebellum and corpus callosum from both adult and fetal ori-
gin. Furthermore, the tumors of this study are located in brain re-
gions other than the cerebellum and corpus callosum, and it was felt
inappropriate to compare tumors from different locations to normal
controls taken from these regions, particularly because unique molec-
ular signatures have been characterized from PA located in supra-
tentorial and posterior fossa regions as previously discussed [17].
Consequently, to standardize the normal control group and reduce
sample heterogeneity, four pooled adult whole-brain samples from
between three and five individuals were selected as controls. Al-
though variation can be seen between the four control samples, it
is critical to note that if any one of these four is removed and the
analysis repeated, the overall expression analysis results are un-
changed with only minor differences in exact fold change values.
Genes Involved in Pediatric PA Development
To investigate pediatric PA development, those genes that showed
a greater than 10-fold change in expression and were either involved
in a KEGG pathway or were well characterized were identified. The
overexpression of SERPINA3 and CHI3L1 provides evidence that the
tumor cells are of astrocytic lineage. SERPINA3 is specifically ex-
pressed in astrocytes and is involved in the expression of astrocytic
Table 4. SD and SEM Are Derived from the Control Values from Normal DNA Obtained from Blood from Four Individuals and One Male and One Female Commercially Available Pooled DNA
Samples (see Table W8 for Raw Data).
Equation of Standard Curve SD Normalized SEM Normalized 95% Reference Range Deletion ≤ Average
Control Copy
Number Minus 95%
Reference Range
Gain ≥ Average
Control Copy
Number Plus 95%
Reference Range
β-actin y = −3.4929x + 30.726
R2 = 0.9928
1p36.32 y = −3.3914x + 29.223 0.05 0.02 0.09 0.91 1.09
R2 = 0.998
BLC7B y = −3.4301x + 28.386 0.06 0.03 0.12 0.88 1.12
R2 = 0.9814
BLC7A y = −3.1059x + 28.599 0.05 0.02 0.10 0.90 1.10
R2 = 0.9934
14q12 y = −3.2777x + 28.844 0.12 0.05 0.23 0.77 1.23
R2 = 0.9979
FOXG1B y = −3.0543x + 30.212 0.12 0.05 0.24 0.76 1.24
R2 = 0.9935
Table 5. Relative Copy Number for Each Gene or Region Was Calculated as Follows: Deletion: ≤ Copy Number of Controls Minus 95% Reference Range of Controls (or 2SD of Controls), Gain: ≥
Copy Number of Controls Plus 95% Reference Range of Controls (or 2SD of Controls).
Tumor 1p36.32 (RP4-703E10) BCL7B* BCL7A (RP11-87C12) 14q12 (RP11-125A5) FOXG1B Promoter†
BAC array/RT-QPCR BAC array/RT-QPCR BAC array/RT-QPCR BAC array/RT-QPCR RT-QPCR
IN1740 Loss/0.54 No CNA/0.38 No CNA/0.53 No CNA/0.71 0.50
IN2356 ND/0.85 ND/0.88 ND/0.79 ND/0.62 1.07
IN2368 No CNA/1.05 Loss/0.31 No CNA/0.85 Loss/0.89 1.12
IN2524 Gain/1.22 Loss/1.08 No CNA/1.01 Loss/0.33 1.30
IN2631 Gain/1.17 No CNA/0.24 No CNA/1.10 Loss/1.10 0.95
IN2674 Loss/0.85 Loss/0.48 No CNA/0.51 Loss/0.85 1.04
IN2788 Loss/0.37 Loss/0.23 No CNA/0.29 No CNA/0.74 0.32
IN2825 ND/0.99 ND/0.66 ND/0.67 ND/0.96 0.69
IN2921 ND/0.93 ND1.03 ND/0.34 ND/0.90 0.38
IN2940 Loss/1.10 No CNA/0.59 No CNA/0.44 Loss/1.01 0.49
IN2969 Gain/0.61 No CNA/0.52 No CNA/0.48 Loss/0.91 0.55
IN3013 Loss/0.46 Loss/0.44 No CNA/0.35 Loss/0.47 0.32
IN3115 Gain/1.12 Loss/0.33 Loss/0.38 Loss/0.98 1.06
IN3156 ND/0.33 ND/0.35 ND/0.34 ND/0.28 0.48
BAC clone alterations for each region are indicated by loss or gain. Blue values correspond to deletions detected by RT-QPCR. Red values correspond to gains detected by RT-QPCR.
*BCL7B is not located under a specific clone but maps within the small region of loss encompassing up to seven clones at 7q11.23. ND indicates not done.
†FOXG1B maps adjacent to clone RP11-125A5 at 14q12.
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markers such as glial fibrillary acidic protein (GFAP) [61,62]. GFAP
was found to be 1.98-fold up-regulated in this study. CHI3L1 is an-
other astrocytic marker that has been used previously as a diagnostic
indicator in astrocytoma [63,64].
Several genes listed in Table 1 have been investigated in other
grades of astrocytoma including T1A-2, ABCC3, CD44, MYT1,
TIMP1, HLA-DPA1, TFPI, CSPG2, CD151, WNT10B, PTK2B,
ENPP2, MBP, MATK, SST, CCK, and FOXG1B. T1A-2 expression
was found to be significantly higher in glioblastoma multiforme
(GBM) compared to anaplastic astrocytoma or diffuse astrocytoma,
and it is a marker of malignant progression [65]. The large fold change
in PA compared to normal brain suggests that this gene is involved in
promoting PA development.
Other genes from this group have functions associated with a range
of tumor characteristics. For example, increased expression of ABCC3
from the multidrug-resistant protein family of ATP-dependent ef-
flux pumps may mediate drug resistance in PA [66]. There is evi-
dence to suggest that CSPG2 protects from oxidative stress induced
apoptosis and promotes tumor growth and angiogenesis [67]. Inter-
estingly, CPGS4 from the same family was found to be up-regulated
in diffuse and malignant astrocytoma in response to platelet-derived
growth factor (PDGF) and increases tumor cell proliferation and
invasion [68,69]. In the present study, CSPG2 and CPGS4 dem-
onstrated a 10.86- and 23.77-fold up-regulation in expression, re-
spectively, in addition to PDGFRA that was also overexpressed by
5.84-fold.
The remaining genes listed in Table 1 either have been associated
with the development of other tumors and cancers or have functions
that could promote or inhibit tumor development. POSTN, for ex-
ample, is overexpressed in more than 80% of human colon cancers
and demonstrates the highest fold change expression in oral squa-
mous cell carcinoma. POSTN enhances cancer growth by preventing
stress-induced apoptosis and enhancing endothelial cell survival pro-
moting angiogenesis [70,71].
Pathways with Differential Gene Expression in Pediatric PA
The Onto-Tools software ranked the KEGG pathways influenced
by the 1844 differentially expressed genes according to the extent of
disruption. In PA, the KEGG pathway antigen processing and pre-
sentation was most affected by differential gene expression. With
the exception of HSP90A, all identified genes involved in this path-
way were up-regulated, including CD74, HLA-DPA1, HLA-DRA,
HLA-DMA, HLA-DRB1, HLA-DMB, HLA-DQB1, HLA-G, CTSS,
HLA-B, KLRC3, HLA-F, HLA-A, PSME2, PDIA3, HLA-E, IFI30,
TAP1, and B2M. A previous study noted an increase in the expres-
sion of genes involved in immune response in PA compared to dif-
fuse astrocytoma, oligodendrogliomas, and normal brain [72]. An
increase in HLA-DPA1 expression in PA compared to anaplastic
astrocytoma was also observed in a second study [73]. Furthermore,
HLA-DR overexpression has been associated with good prognosis
in large-bowel carcinoma and serous ovarian tumors [74,75]. The
Figure 4. Loss of between two and seven contiguous BAC clones at 7q11.23 in seven PA. The rows of colored spots represent individual
tumors and single BAC clones losses at 7q11.23. The distance between each spot is representative of the BAC clone binding locations
on DNA.
Table 6. BAC Clone Losses and Differential Gene Expression in the Same Region in Pediatric PA.
Clone Location Clone Name Clone Alteration Gene Located in Clone Region Fold Change in Expression Description
7q11.23 RP11-35P20, B315H11, CITB-51J22, B270D13,
B39H04, RP11-137E8, RP11-89A20
Loss BCL7B −2.14 B-cell CLL/lymphoma 7B
9p21.2–p23 RP11-163F8 Loss SH3GL2 −6.94 SH3-domain GRB2-like 2
10q26.3 RP11-122K13 Loss DRD1IP −35.09 Dopamine receptor D1 interacting protein
12q24.33 RP11-87C12 Loss BCL7A −2.98 B-cell CLL/lymphoma 7A
14q12 RP11-125A5 Loss FOXG1B −325.73 Forkhead box G1B
17q21.31 AC100793.8 Loss TUBG2 −2.28 Tubulin, gamma 2
CNTNAP1 −2.99 Contactin-associated protein 1
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up-regulation of immune response genes in PA may contribute to the
benign behavior of this tumor type.
The KEGG phosphatidylinositol (PI3K) signaling system and the
mitogen-activated protein kinase (MAPK) signaling pathway are
ranked as the third and fifth, respectively, according to the extent
of differential gene expression in PA (Table 2). Altered signaling in
these pathways through increased receptor stimulation and disrupted
tumor suppressor or oncogene function has been characterized in
other grades of astrocytoma particularly primary and secondary adult
GBM [76].
Genomic Aberrations Previously Identified in Pediatric PA
Few studies have identified nonrandom whole-chromosome or
arm aberrations in PA of the pediatric population. As discussed in
the introduction, Jones et al. [25] only identified CNAs in children
older than 10 years using aCGH. Furthermore, using analog CGH,
Sanoudou et al. [5] identified five PA (12%) with whole-chromosome
aberrations, and all were from patients 7 years or older (four patients
were 10 years or older). Of the tumors in this study, 59% were from
patients older than 7 years and 41% were from patients older than
10 years. Possibly, whole-chromosome or arm aberrations maybe more
common in PA of older children. In our study, five cases (45%) were
from patients 7 years or older and only one case was from a patient
older than 10 years. This may explain why we have not identified
any whole-chromosome or arm aberrations in the tumors of this pa-
tient cohort.
Genomic Loss in Regions of LCVs in Pediatric PA
Of 97 BAC clones altered in PA, 40% were located in regions of
LCV present in the normal population [77–84]. The role of LCVs
(which involve gain or loss of hundreds of kilobases of genomic
DNA) in phenotypically normal individuals is not clear [77]. How-
ever, LCVs at 14q12 were found to be present in DNA from 50% of
chronic myeloid leukemia and pediatric solid tumors compared to an
incidence of 10% in somatic DNA of healthy control individuals,
suggesting that acquired or inherited LCVs at 14q12 may be associ-
ated with the onset or progression of neoplasia [85]. In our study, the
incidence of 14q12 aberrations in PA was 79%, as identified by com-
bined aCGH and RT-QPCR analyses. Further investigations are nec-
essary to establish the incidence of LCVs in somatic DNA of PA
patients to determine whether 14q12 aberrations are inherited or
are acquired during tumor development.
Correlation of CNAs and Gene Expression in Pediatric PA
Loss of individual clones at 9p21.2–p23, 10q26.3, 12q24.33, and
17q21.31 and a small region of up to seven adjacent clones at 7q11.23
correlated with differential gene expression. Crucially, although BAC
array analysis did not identify genomic loss in all tumors, the down-
regulation of genes including SH3GL2 at 9p21.2–p23, DRD1IP at
10q26.3, BCL7A at 12q24.33, TUB2 and CNTNAP1 at 17q21.31,
and BCL7B at 7q11.23 was seen in all cases. Furthermore, RT-QPCR
analysis of relative DNA copy number of BCL7B at 7q11.23 and
BCL7A at 12q24.33 identified loss in 12 (86%) of 14 tumors. BCL7B
and BCL7A are from the same gene family and share 90% homology.
BCL7B maps to a region deleted in the congenital disorder Williams
syndrome, although little is known about its function [86]. BCL7A
is a putative tumor suppressor gene, which is hypermethylated in
the primary cutaneous T-cell lymphoma [87]. Earlier studies have
demonstrated the involvement of the BCL7A locus in a recurrent
break point in B-cell lymphomas and a complex translocation and re-
arrangement in specific cell lines [88]. Expression profiling of mycosis
fungoides, a common cutaneous T-cell lymphoma and B-cell lymphoma,
identified the down-regulation of BCL7A as part of molecular sig-
natures that could distinguish mycosis fungoides and inflammatory
dermatoses and distinct types of diffuse large B-cell lymphoma [89,90].
The loss of BCL7A has also been associated with disrupted NF-κB
signaling and unfavorable prognosis in patients with B-cell lympho-
mas, suggesting that this gene has tumor suppressor properties [91].
The clone aberrations detected at 14q12 by BAC array analysis
could only be confirmed by RT-QPCR in two cases. A previous
study also failed to confirm RP11-125A5 loss [47]. This region is
a common site for duplication and deletion events in hepatoblastoma,
which may explain the discrepancies between CNA detected by BAC
array and RT-QPCR analysis in the PA of this study [92]. However,
FOXG1B maps adjacent to clone RP11-125A5 and shows significant
down-regulation in all PA. Real-time quantitative polymerase chain
reaction analysis of relative DNA copy number of the FOXG1B pro-
moter demonstrated genomic loss in almost 60% of tumors exam-
ined, indicating that genomic loss is an important mechanism in the
underexpression of this gene.
FOXG1B is an oncogenic transformer and transcriptional repressor,
which interacts with Groucho, Hes, and Smad proteins [93,94]. More
importantly, FOXG1B has been proposed as a major FoxO forkhead
transcription factor that acts as a signal transducer between the Smad,
PI3K, and FoxG1B pathways. The activity of these pathway interac-
tions has been shown to be involved in the resistance to transforming
growth factor beta (TGFβ)–mediated cytostasis during telencephalic
neuroepithelium development and in GBM cells [95]. The involve-
ment of FOXG1B in PI3K (the pathway most affected by the differen-
tial gene expression in PA) highlights the impact FOXG1B disruption
may have on intracellular signaling. The location of this gene in a
region of LCV at 14q12 also suggests that some individuals may
be predisposed to PA development.
Reduction of SH3GL2 expression correlated with loss at 9p21.2–
p23. A recent study indicates that SH3GL2 is involved in the devel-
opment and progression of laryngeal squamous cell carcinoma and
expression levels correlate with pathologic classification [96]. The ex-
pression of SH3GL2 also correlates with distinct stages of intestinal-
type gastric cancer, although a functional role in tumorigenesis has
not yet been determined [97].
TUBG2, located at 17q21.31, shares 97.3% amino acid identity
with TUBG1, and the two genes are coexpressed in a variety of tissues.
This suggests that the functions of TUBG1 and TUBG2 are similar,
both having a significant role in the organization of the microtubule
cytoskeleton [98]. CNTNAP1, also located at 17q21.31, is transcribed
predominantly in the brain, and the architecture of the protein extra-
cellular domain is similar to that of neurexins. CNTNAP1 plays an
important role in the creation and maintenance of paranodal regions
of myelinated axons, enabling recruitment and activation of intracellu-
lar signaling pathways in neurons [99]. DRD1IP maps to 10q26.3 and
encodes a brain-specific dopamine receptor 1–interacting protein in-
volved in calcium signaling [100]. A role for these genes in tumor de-
velopment has yet to be established.
Promoter Hypermethylation in Pediatric PA
Down-regulation of gene expression through promoter hyper-
methylation is an important mechanism of transcriptional silencing
in many tumors. Hypermethylation of the six genes investigated in
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this study has been detected in more than 30% of gastric carcinoma,
lung cancer, and renal cell carcinoma. Moreover, CCNA1 was hyper-
methylated in 100% of colorectal adenoma [28–33]. All six genes
demonstrated a twofold and significant down-regulation in PA com-
pared to normal brain, but hypermethylation of gene promoter re-
gions was not detected. Only one previous study has investigated
hypermethylation in pediatric PA involving MGMT, GSTP1, DAPK1,
p14ARF, THBS-1, TIMP-3, p73, p16INK4A, RB-1, and TP53. Hyper-
methylation of p16INK4A was most frequent occurring in 46% of cases.
However, five of the remaining genes were hypermethylated in less
than 8% of cases [101]. It is possible that methylation is not the pre-
dominant mechanism of gene silencing in PA development but that
other epigenetic processes such as histone modification and microRNA
play a more significant role.
We have clearly demonstrated that PA have distinct expression pro-
files compared to normal whole brain. We have identified two key sig-
naling pathways (PI3K and MAPK) that contribute toward tumor
development. Large regions of chromosome alterations were not iden-
tified in PA, although 97 individual BAC clones and a small region
on chromosome 7 were lost and/or gained. This is the first study to
establish a correlation between small regions of genomic CNA and dif-
ferential gene expression in PA. The down-regulation of gene family
members BCL7B and BCL7A due to independent CNAs suggests a
tumor suppressor role for these genes in PA. Furthermore, we have
demonstrated that genomic alterations in a region of LCV at 14q12
may predispose individuals to tumor development. The accompanying
loss of FOXG1B expression in all samples together with its involve-
ment in PI3K signaling provides compelling evidence that this gene
may play a significant role in the development of pediatric PA.
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Table W1. Clinical Data for Pediatric PA Patients.
Tumor Age* Sex† Location Survival‡
IN1350 4.3 M Posterior fossa Unknown
IN1740 8 M Posterior fossa 160 (A)
IN2110 2.7 M Posterior fossa DIS 125 (A)
IN2356 4 M Cerebellum 142 (A)
IN2368 8 F Posterior fossa DIS 87 (A)
IN2524 4 F Midline-posterior fossa DIS 39 (A)
IN2604 6 F Chiasmatic Unknown
IN2631 4 F Cerebellum 21 (A)
IN2674 5 M Cerebellum 112 (A)
IN2788 9 M Posterior fossa 45 (A)
IN2825 2.75 F Posterior fossa 104 (A)
IN2921 3 M Posterior fossa 48 (A)
IN2940 1.75 M Posterior fossa 74 (A)
IN2969 3.5 F Posterior fossa 57 (A)
IN3013 11.5 M Posterior fossa 58 (A)
IN3017 8.25 F Posterior fossa 59 (A)
IN3115 3.5 F Optic Pathway 33 (A)
IN3126 9 M Posterior fossa 31 (A)
IN3156 1.9 M Posterior fossa 1 (A)
*Age in years at diagnosis.
†F indicates female; M , male.
‡Survival in months from date of diagnosis. A indicates alive; DIS, discharged from hospital.
Table W2. Genomic Copy Number RT-QPCR Primer and Probe Sequences and Concentrations.
Locus Sense 5′–3′ Antisense 5′–3′ Probe 5′–3′ Primer/Probe Concentrations Fluorescent Label
1p36.32–1p36.33 gaggagttgctctctgcatcct aacatgccttctgctctggatt cgcagctcaagagtaga Sense 300 nM FAM
Antisense 900 nM
Probe 200 nM
7q11.23 (BCL7B) gcttacccactgttaggacatgttc ggcagtatcatgactacggtgatg tcctaaaccaatcccgc Sense 300 nM FAM
Antisense 900 nM
Probe 200 nM
12q24.33 (BCL7A) aggtgtagaaatgctggttgcat tttggcacttccctgatatctgt tgagaagatgtggtccc Sense 300 nM FAM
Antisense 900 nM
Probe 200 nM
14q12 acagaaacggacttggagaagaag gctcagcgaatggctaattcttt Accgtctgactgatgaa Sense 300 nM FAM
Antisense 900 nM
Probe 200 nM
FOXG1B (promoter) tgtggaggacaagttgttcatttg gctgataacatcttagggccagatt tgtgttctgcagtattg Sense 300 nM FAM
Antisense 900 nM
Probe 200 nM
β-actin acgaggcccagagcaagag gacgatgccgtgctcgat caccctgaagtaccc Sense 900 nM VIC
Antisense 900 nM
Probe 200 nM
Table W3. MSP Primer Sequences, Annealing Temperatures, and Product Sizes for All Genes Analyzed.
Gene Sense 5′–3′ Antisense 5′–3′ Annealing Temperature (°C) PCR Product Size (bp)
CCNA1 (M) tcgtcgcgttttagtcgt (M) cgttctcccaacaaccg 54.3 200
(U) gggtagttttgttgtgttttagtt (U) ccattctcccaacaaccac 55.1 200
CDKN1C (M) gggttcgcgcgtataaa (M) atacgaaaaacgcgacgac 54.7 200
(U) gggtggggtttgtgtgtat (U) aaaacacaacaactacctaactatcc 53.7 200
DAPK1 (M) gtcggatcgagttaacgtcg (M) aaacgccgaccccaaa 56.9 70
(U) gtttgtgagtgagtgtttagtttg (U) tctaattacctaaaaccaaattcatca 57.6 70
PRDM2 (M) cgacggcgtagggttaagg (M) ctatttcgccgaccccg 58.7 150
(U) ggtgatggtgtagggttaagggt (U) cactatttcaccaaccccaaca 58.7 150
REPRIMO (M) tgcgagtgagcgtttagttc (M) ttacctaaaaccgaattcatc 55.1 100
(U) gtttgtgagtgagtgtttagttgg (U) tctaattacctaaaaccaaattcatca 55.7 100
SPINT2 (M) cgagaaggtcgggcg (M) caaccgttaaaatctcgcg 55.7 150
(U) gttgagaaggttgggtgtttt (U) caccaaccattaaaatctcac 54.3 150
Table W4. Sequencing Primers, Annealing Temperatures, and Product Sizes for All Genes Analyzed.
Gene Sense 5′–3′ Antisense 5′–3′ Annealing Temperature (°C) PCR Product Size (bp)
CCNA1 (Set1) ggggaagattttttgtggg (Set1) tcaaacccctaaaaacccaac 56 525
(Set2) tatagttggagttggagggt (Set2) caaaacctacctaaacccc 54 490
CDKN1C (Set1) gtggtgttgttgaaattga (Set1) cactaatactaaaaaaatcccac 49 420
(Set2) gtgggatttttttagtattagtg (Set2) accaaaacactaaacaactactc 49 375
DAPK1 (Set1) ggaaggtagggatttaaaaa (Set1) accaataaaaaccctacaaac 49 380
(Set2) gtttgtagggtttttattggt (Set2) ccttaaccttcccaattact 49 450
(Set3) gagtaattgggaaggttaagg (Set3) tcactaaaaacaatctctctcca 52.5 380
PRDM2 (Set1) tgggaatagtaagttttttaaggg (Set1) caataaccaccacccaacc 55 420
(Set2) ggttgggtggtggttatt (Set2) aaaaccccaaataacccca 55 600
REPRIMO (Set1) gggtttgtttttggttaatagtag (Set1) caaatttacttcacccaatctc 52.5 390
SPINT2 (Set1) aggaaggaatttataggaaagttg (Set1) ccaaataccaaaaccccc 53.5 575
(Set2) gggggttttggtatttgg (Set2) attctccctactcaaacccc 57 320
Figure W1. (a) Dendrogram representing the gene expression profile of 13 of 89 genes used by Wong et al. [16] to distinguish possible
subgroups in pediatric PA. The dendrogram color saturation is proportional to the magnitude of the difference from the mean, ranging
from red (overexpressed) to green (underexpressed). (b) Gene expression profile of 13 of 89 genes used by Wong et al. [16] to distin-
guish possible subgroups in pediatric PA. The 19 PA are ordered according to expression profile similarity by hierarchical clustering.
Table W6. KEGG Pathways Involved in the Onto-Tools Analysis Approach.
KEGG ID Pathway Name
1510 Neurodegenerative disorders
4010 MAPK signaling pathway
4020 Calcium signaling pathway
4060 Cytokine–cytokine receptor interaction
4070 Phosphatidylinositol signaling system
4080 Neuroactive ligand–receptor interaction
4110 Cell cycle
4120 Ubiquitin-mediated proteolysis
4130 SNARE interactions in vesicular transport
4140 Regulation of autophagy
4150 mTOR signaling pathway
4210 Apoptosis
4310 Wnt signaling pathway
4330 Notch signaling pathway
4340 Hedgehog signaling pathway
4350 TGFβ signaling pathway
4360 Axon guidance
4370 VEGF signaling pathway
4510 Focal adhesion
4512 ECM–receptor interaction
4514 Cell adhesion molecules (CAMs)
4520 Adherens junction
4530 Tight junction
4540 Gap junction
4610 Complement and coagulation cascades
4612 Antigen processing and presentation
4620 Toll-like receptor signaling pathway
4630 Jak–STAT signaling pathway
4650 Natural killer cell mediated cytotoxicity
4660 T-cell receptor signaling pathway
4662 B-cell receptor signaling pathway
4664 Fc epsilon RI signaling pathway
4670 Leukocyte transendothelial migration
4710 Circadian rhythm
4720 Long-term potentiation
4730 Long-term depression
4740 Olfactory transduction
4742 Taste transduction
4810 Regulation of actin cytoskeleton
4910 Insulin signaling pathway
4912 GnRH signaling pathway
4920 Adipocytokine signaling pathway
4930 Type II diabetes mellitus
4940 Type I diabetes mellitus
4950 Maturity onset diabetes of the young
5010 Alzheimer disease
5020 Parkinson disease
5030 Amyotrophic lateral sclerosis (ALS)
5040 Huntington disease
5050 Dentatorubropallidoluysian atrophy (DRPLA)
5060 Prion disease
5120 Epithelial cell signaling in Helicobacter pylori infection
5210 Colorectal cancer
Table W7. RT-QPCR Was Used to Validate Expression Results Generated through Microarray Analysis.
Tumor TIMP1 MCL1 SPINT2 CCN1A MAPK1 MATK
Array/RT-QPCR Array/RT-QPCR Array/RT-QPCR Array/RT-QPCR Array/RT-QPCR Array/RT-QPCR
IN1350 10.95/5.46 2.88/1.89 0.24/0.02 0.19/0.00 0.50/0.16 0.04/0.01
IN1740 43.15/35.92 2.281.89 0.18/0.03 0.28/0.00 0.57/0.26 0.03/0.01
IN2110 12.11/9.60 2.33/1.39 0.31/0.03 0.03/0.00 0.43/0.20 0.03/0.01
IN2368 10.20/20.49 5.63/2.34 0.07/0.02 0.17/0.00 0.67/0.29 0.05/0.01
IN2524 13.52/9.54 6.42/1.53 0.24/0.03 0.17/0.00 0.68/0.26 0.03/0.00
IN2604 26.74/20.16 5.25/2.44 0.17/0.02 0.19/0.02 0.85/0.11 0.07/0.00
IN2631 18.05/5.58 6.15/0.78 0.25/0.02 0.32/0.01 0.72/0.17 0.02/0.00
IN2674 7.12/6.26 3.43/1.50 0.57/0.16 0.25/0.02 0.50/0.46 0.03/0.03
IN2825 27.41/32.00 5.43/3.19 0.17/0.03 0.40/0.05 0.46/0.22 0.06/0.01
IN2921 39.89/26.05 3.68/1.16 0.60/0.05 0.14/0.00 0.37/0.13 0.05/0.01
IN2940 17.56/7.78 4.93/1.30 0.28/0.04 0.22/0.00 0.38/0.17 0.03/0.01
IN2969 11.15/9.89 3.57/1.68 0.26/0.05 0.26/0.03 0.48/0.27 0.04/0.01
IN3013 14.69/13.42 3.95/1.33 0.33/0.05 0.14/0.00 0.49/0.17 0.05/0.00
IN3017 13.95/23.92 3.15/3.50 0.13/0.05 0.22/0.01 0.60/0.32 0.04/0.00
IN3126 11.68/11.69 7.56/1.00 0.38/0.08 0.31/0.00 0.67/0.26 0.05/0.01
IN3156 30.88/19.93 3.91/0.89 0.30/0.04 0.26/0.03 0.45/0.18 0.02/0.01
The comparative CTmethod was used to determine the relative ratio of expression results for each gene. These were corrected by β-actin and referenced to normal brain controls. The relative quantitative
value shown previously is expressed as 2−ΔΔCT.
Ta
bl
e
W
9.
St
an
da
rd
C
ur
ve
M
et
ho
d
(P
E
A
pp
lie
d
B
io
sy
st
em
s,
W
ar
ri
ng
to
n,
U
K
)
U
se
d
to
C
al
cu
la
te
th
e
R
el
at
iv
e
D
N
A
C
op
y
N
um
be
r
of
Fi
ve
R
eg
io
ns
of
In
te
re
st
U
si
ng
β-
ac
tin
as
an
E
nd
og
en
ou
s
C
on
tr
ol
.
Tu
m
or
β-
ac
tin
*
1p
36
.3
2*
N
or
m
al
iz
ed
1p
36
.3
3
C
op
y
N
um
be
r
BC
L7
B
*
N
or
m
al
iz
ed
BC
L7
B
C
op
y
N
um
be
r
BC
L7
A
*
N
or
m
al
iz
ed
BC
L7
A
C
op
y
N
um
be
r
14
q1
2*
N
or
m
al
iz
ed
14
q1
2
C
op
y
N
um
be
r
FO
XG
1B
Pr
om
ot
er
*
N
or
m
al
iz
ed
FO
XG
1B
C
op
y
N
um
be
r
IN
17
40
6.
70
6.
89
1.
03
0.
54
5.
15
0.
77
0.
38
5.
55
0.
83
0.
53
8.
29
1.
24
0.
71
9.
33
1.
39
0.
50
IN
23
56
10
.9
0
17
.6
5
1.
62
0.
85
19
.4
5
1.
79
0.
88
13
.4
4
1.
24
0.
79
11
.6
9
1.
07
0.
62
32
.3
6
2.
98
1.
07
IN
23
68
12
.5
8
25
.1
5
2.
00
1.
05
7.
89
0.
63
0.
31
16
.7
0
1.
33
0.
85
3.
20
1.
55
0.
89
39
.2
0
3.
11
1.
12
IN
25
24
4.
53
10
.5
4
2.
33
1.
22
10
.0
0
2.
21
1.
08
7.
13
1.
57
1.
01
2.
63
0.
58
0.
33
16
.4
2
3.
63
1.
30
IN
26
31
4.
48
9.
99
2.
23
1.
17
2.
16
0.
48
0.
24
7.
69
1.
72
1.
10
3.
37
1.
91
1.
10
11
.8
9
2.
65
0.
95
IN
26
74
1.
32
2.
15
1.
63
0.
85
1.
29
0.
99
0.
48
1.
04
0.
79
0.
51
1.
94
1.
47
0.
85
3.
85
2.
92
1.
04
IN
27
88
9.
79
6.
94
0.
71
0.
37
4.
58
0.
47
0.
23
4.
42
0.
45
0.
29
12
.6
7
1.
29
0.
74
8.
82
0.
90
0.
32
IN
28
25
4.
47
8.
48
1.
90
0.
99
6.
03
1.
35
0.
66
4.
71
1.
05
0.
67
7.
44
1.
67
0.
96
8.
62
1.
93
0.
69
IN
29
21
16
.8
7
7.
66
1.
79
0.
93
9.
08
2.
12
1.
03
8.
98
0.
53
0.
34
6.
73
1.
57
0.
90
4.
54
1.
06
0.
38
IN
29
40
11
.1
2
23
.4
4
2.
11
1.
10
13
.3
6
1.
20
0.
59
7.
63
0.
69
0.
44
4.
04
1.
76
1.
01
15
.1
1
1.
36
0.
49
IN
29
69
5.
38
6.
29
1.
17
0.
61
5.
67
1.
06
0.
52
4.
01
0.
75
0.
48
8.
49
1.
58
0.
91
8.
31
1.
55
0.
55
IN
30
13
7.
68
6.
71
0.
87
0.
46
6.
94
0.
91
0.
44
4.
26
0.
56
0.
35
6.
29
0.
82
0.
47
6.
93
0.
90
0.
32
IN
31
15
17
.7
0
37
.9
3
2.
14
1.
12
12
.0
4
0.
68
0.
33
10
.5
7
0.
60
0.
38
4.
17
1.
71
0.
98
52
.6
1
2.
97
1.
06
IN
31
56
16
.4
7
10
.4
3
0.
64
0.
33
11
.6
8
0.
71
0.
35
8.
71
0.
53
0.
34
7.
83
0.
48
0.
28
22
.1
2
1.
35
0.
48
C
on
tr
ol
s
Fe
m
al
e
12
.7
5
24
.7
1
1.
94
1.
02
25
.9
6
2.
04
1.
00
20
.9
0
1.
64
1.
05
20
.1
4
1.
58
0.
91
38
.0
5
2.
88
1.
03
M
al
e
15
.2
9
28
.6
8
1.
88
0.
98
31
.3
3
2.
05
1.
00
23
.6
9
1.
55
0.
99
28
.1
4
1.
84
1.
06
40
.8
8
2.
68
0.
96
IN
28
86
16
.8
0
30
.9
8
1.
84
0.
97
33
.4
4
1.
99
0.
97
25
.6
9
1.
53
0.
98
31
.2
9
1.
86
1.
07
45
.3
4
2.
70
0.
97
IN
28
27
11
.9
0
23
.1
2
1.
94
1.
02
24
.7
6
2.
08
1.
02
19
.2
4
1.
62
1.
03
21
.1
2
1.
77
1.
02
31
.9
0
2.
68
0.
96
IN
27
66
13
.2
6
24
.9
6
1.
88
0.
99
26
.1
2
1.
97
0.
96
20
.7
0
1.
56
1.
00
21
.4
9
1.
62
0.
93
38
.0
4
2.
87
1.
03
IN
28
87
14
.3
5
28
.2
6
1.
97
1.
03
30
.7
5
2.
14
1.
05
21
.4
8
1.
50
0.
96
25
.4
2
1.
77
1.
02
42
.3
4
2.
95
1.
06
C
on
tr
ol
av
er
ag
e
1.
91
1.
00
2.
05
1.
00
1.
57
1.
00
1.
74
1.
00
2.
79
1.
00
*I
nd
ic
at
es
th
e
av
er
ag
e
na
no
gr
am
s
of
D
N
A
fo
r
th
e
gi
ve
n
re
gi
on
ge
ne
ra
te
d
fr
om
th
e
st
an
da
rd
cu
rv
e.
T
he
co
py
nu
m
be
r
of
ea
ch
re
gi
on
or
ge
ne
fo
r
ea
ch
tu
m
or
is
re
la
tiv
e
to
th
e
av
er
ag
e
co
nt
ro
l
no
rm
al
iz
ed
va
lu
e.
Figure W2. (a) MSP results for CDKN1C, PRDM2, SPINT2, REPRIMO, CCNA1, and DAPK1 in pediatric astrocytomas. These results show
PCR products for primer sets designed to amplify unmethylated or methylated promoter regions. M indicates methylated products and
U indicates unmethylated products for each tumor. (b) Sequencing data for DAPK1 in PA IN3115 and IN2940 and normal brain. CpG sites
where methylation could occur are indicated in the original sequence by a blue box. Unmethylated cytosine residues are converted to
uracil residues that, during amplification, become thymidine residues. The bisulfite-treated sequence illustrates no methylation.
Figure W3. The dendrogram is colored by 7178 genes that were present in all samples and used for this unsupervised hierarchical
clustering approach. The samples with red branches are pediatric PA, those with yellow branches are adult normal controls, and those
with light blue branches are fetal normal controls. The dendrogram color saturation is proportional to the magnitude of the difference
from the experiment median. Cer indicates cerebellum; Cor Cal, corpus callosum; WB, whole brain.
